Sugi Predict

Sugi Predict / Targets / MAN2A1

MAN2A1

Alpha-mannosidase 2 · Q16706 · MAN2A1 on Sugi Atlas →

658 patent compounds predicted against MAN2A1, 243 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL13808578 SCHEMBL13808578 1.00 15/20
SCHEMBL13808575 SCHEMBL13808575 0.85 15/20
SCHEMBL3994042 SCHEMBL3994042 0.76 15/20
SCHEMBL4286219 SCHEMBL4286219 0.71 15/20
SCHEMBL3997325 SCHEMBL3997325 0.64 15/20
SCHEMBL13808576 SCHEMBL13808576 0.51 15/20
SCHEMBL4001127 SCHEMBL4001127 0.71 14/20
SCHEMBL4001130 SCHEMBL4001130 0.71 14/20
SCHEMBL2433156 SCHEMBL2433156 0.53 10/20
SCHEMBL28094433 SCHEMBL28094433 0.51 8/20
SCHEMBL8599119 SCHEMBL8599119 0.51 8/20
SCHEMBL28647014 SCHEMBL28647014 0.49 8/20
SCHEMBL11190081 SCHEMBL11190081 0.47 7/20
SCHEMBL15574485 SCHEMBL15574485 0.40 6/20
SCHEMBL28452986 SCHEMBL28452986 0.39 6/20
SCHEMBL20016427 SCHEMBL20016427 0.44 5/20
SCHEMBL4129418 SCHEMBL4129418 0.42 5/20
SCHEMBL28030149 SCHEMBL28030149 0.41 5/20
SCHEMBL6857324 SCHEMBL6857324 0.40 5/20
SCHEMBL14119700 SCHEMBL14119700 0.40 5/20

Clinical trials — most relevant to MAN2A1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Interventional Study to Assess Efficacy and Safety of Velmanase Alfa in Patients With Alpha Mannosidosis PHASE3WITHDRAWN
A Placebo-Controlled Phase 3 Trial of Repeated Lamazym Treatment of Subjects With Alpha-Mannosidosis PHASE3COMPLETED
Dose Finding Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis PHASE2UNKNOWN
Long-term Efficacy and Safety of Lamazym for the Treatment of Patients With Alpha-Mannosidosis PHASE2COMPLETED
Trial on Safety and Efficacy of Velmanase Alfa Treatment in Pediatric Patients With Alpha-Mannosidosis PHASE2COMPLETED
24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG PHASE2COMPLETED
Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients PHASE2ENROLLING_BY_INVITATION
Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy PHASE2COMPLETED
Recombinant Human Mannose-Binding Lectin (MBL) in Treating Young Patients With MBL Deficiency and Fever and Neutropenia PHASE1WITHDRAWN
Safety Study of Recombinant Human Alpha-mannosidase for the Treatment of Patients With Alpha-mannosidosis PHASE1COMPLETED
Biomarker for Mannosidosis Disease (BioMannosidosis) nanWITHDRAWN
The Natural History of Alpha-Mannosidosis nanCOMPLETED
Registry Gangliosidoses nanUNKNOWN
Analysis of Velmanase Alfa (Lamzede®)'s Effects in the Body of Children With Alpha-Mannosidosis Under the Age 3 nanRECRUITING
Clinical Biomarkers in Alpha-mannosidosis nanCOMPLETED
Biomarker for Mucolipidosis Disorder Type I, II, III, IV (BioML) nanWITHDRAWN
Italian Anderson Fabry Disease Cardiovascular Registry nanRECRUITING
Using D-Galactose as a Food Supplement in Congenital Disorders of Glycosylation nanCOMPLETED
Lyso-Gb1 as a Long-term Prognostic Biomarker in Gaucher Disease nanCOMPLETED
Natural History of Glycosphingolipid Storage Disorders and Glycoprotein Disorders nanRECRUITING
the Role of cArdiac Inflammation, endoThelial Dysfunction, and FIbrosis in fabrY Disease nanRECRUITING
Longitudinal Studies of the Glycoproteinoses nanCOMPLETED
Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2) nanWITHDRAWN
Detection of Pompe Disease in Adult Patients With Myopathies of Uncertain Origin or With Asymptomatic Hyper-CK-emia nanUNKNOWN
Fibrosis, Inflammation, Oxygenation of Renal Tissue In FabrY Disease nanRECRUITING
Glycosylation in Patients With Galactosaemia nanCOMPLETED
Characterization of the Patient Population With Galactosialidosis nanCOMPLETED
Effect of Migalastat on Cardiac Involvement in Fabry Disease nanCOMPLETED
A Study to Evaluate and Characterize the Effect of Pharmacological Chemicals on Blood From Patients With Gaucher Disease nanCOMPLETED
BMN 110 US Expanded Access Program nanAPPROVED_FOR_MARKETING

Related proteins — ESM-2 sequence neighbours (a MAN2A1 binder may also engage these)

ProteinNameSimilarity
P27046 — 1.000 P27046 →
P28494 — 0.997 P28494 →
Q8LPJ3 — 0.989 Q8LPJ3 →
Q9FKW9 — 0.984 Q9FKW9 →
Q9LFR0 — 0.981 Q9LFR0 →
C0HJB3 — 0.980 C0HJB3 →
Q24451 — 0.980 Q24451 →
P94078 — 0.977 P94078 →
O18497 — 0.976 O18497 →
F4HTM3 — 0.976 F4HTM3 →
Q6DE40 — 0.975 Q6DE40 →
Q9GLD3 — 0.975 Q9GLD3 →
Q8K2I4 — 0.974 Q8K2I4 →
Q9FF10 — 0.974 Q9FF10 →
Q2V905 — 0.974 Q2V905 →
Q9V3L1 — 0.973 Q9V3L1 →
Q29444 — 0.973 Q29444 →
Q811A3 — 0.972 Q811A3 →
Q8K1B9 — 0.972 Q8K1B9 →
O09159 — 0.972 O09159 →
Q966W3 — 0.971 Q966W3 →
Q95327 — 0.971 Q95327 →
Q8GX69 — 0.971 Q8GX69 →
Q8RX87 — 0.971 Q8RX87 →
Q9FNA3 — 0.971 Q9FNA3 →
Q07891 — 0.971 Q07891 →
W8E7D1 — 0.971 W8E7D1 →
Q84M89 — 0.971 Q84M89 →
Q00662 — 0.970 Q00662 →
Q9WTZ2 — 0.970 Q9WTZ2 →